Long-Term CD8 T-cell Depletion

Absolute Antibody is offering engineered mouse-anti-mouse versions of the anti-mouse CD8 antibody YTS 169.4, YTS 105.18 and YTS 156.7 for improved performance in vivo.

- Reduced immunogenicity as antibody species is matched to host
- No reduction in depletion through anti-drug-antibodies after +60 d
- Fc Silent formats available as non-depleting blockers and controls
- Multiple clones available for ultra-long treatments

Recombinant Anti-CD8 antibody maintains T-cell depletion for over 60 days when reformatted as a mouse IgG2a, where original rat IgG2b format loses efficacy after two weeks.

Figure: CD8+T-cell population in mice treated with anti-CD8 antibodies for depletion and isotype controls. Mouse IgG2a format is shown in purple and Rat IgG2b is shown in blue. Injections of 250 µg every 4 days. Unpublished data, courtesy and property of the University of Basel, Switzerland.

Other reformatted antibodies available against depleting targets including Ly6G, CD4, CD25 and many more. Check out our range of mouse immune checkpoint targets overleaf.